Following on from the recent news in February 2023 that Duke NUS and NHCS scientists found that blocking an immune regulating protein Interleukin-11 (IL-11) can stop and even reverse kidney damage caused by acute and chronic kidney disease in mouse models Boehringer Ingelheim (Pharma company) have announced they are starting clinical development on an IL-11 Inhibitor with a Phase 1 study.
This is only shown so far in mouse models. But if this proves successful in clinical development it appears we could regenerate already damaged kidneys to some degree.